BRAF and melanoma: This is further supported by a recent phase 3 COMBI-I clinical trial (NCT02967692) that examined the efficacy of a novel PD-1 inhibitor (spartalizumab) in combination with dabrafenib and trametinib in patients with unresectable and/or metastatic BRAF V600E mutant melanomas.